CytoDyn to Present at 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 10:00 AM Eastern
February 05 2014 - 7:35AM
Business Wire
Presentation to highlight Company’s clinical
development plans for PRO 140, a monoclonal CCR5 antibody with the
potential to change the treatment paradigm for patients with
HIV/AIDS
CytoDyn Inc. (OTCQB: CYDY), a biotechnology
company focused on the development of new therapies for combating
infection with immune deficiency viruses, announced today the
Company will be presenting at the 16th Annual BIO CEO &
Investor Conference on Monday, February 10, 2014 at 10:00 AM
Eastern. Hosted by the Biotechnology Industry Organization (BIO),
the 16th Annual BIO CEO & Investor Conference will take place
February 10-11 at the Waldorf Astoria in New York City.
Nader Pourhassan, Ph.D., President and CEO, will present the
Company’s 2014 corporate business outlook, including clinical
development plans and milestones for lead product candidate PRO
140.
The live audio webcast of the presentation will be available in
the Investor Relations section of the company’s website at
www.cytodyn.com. A webcast replay will be available approximately
two hours after the presentation ends and will be accessible for 90
days.
About PRO 140
PRO 140 belongs to a new class of HIV/AIDS therapeutics --
viral-entry inhibitors -- that are intended to protect healthy
cells from viral infection. PRO 140 is a humanized monoclonal
antibody directed against CCR5, a molecular portal that HIV uses to
enter cells.
PRO 140 has been the subject of four Phase 1/1b and two Phase 2a
clinical trials, each of which demonstrated PRO 140’s ability to
significantly reduce HIV viral load in human test subjects, and has
also been designated a “fast track” product candidate by the FDA.
The PRO 140 antibody appears to be a powerful antiviral agent while
not being a drug, leading to potentially fewer side effects and
less frequent dosing requirements as compared to daily drug
therapies currently in use.
About CytoDyn
CytoDyn is a biotechnology company focused on developing
subcutaneously delivered humanized cell-specific monoclonal
antibodies (mAbs) as entry inhibitors for the treatment and
prevention of Human Immunodeficiency Virus (HIV). The Company has
one of the leading mAbs under development for HIV infection, PRO
140, which is a Late Stage 2 humanized mAb with demonstrated
antiviral activity in man. PRO 140 blocks the HIV co-receptor CCR5
and clinical trial results thus far indicate that it does not
affect the normal function of the cell. Results from Phase 1/1b and
Phase 2a human clinical trials have shown that PRO 140 can
significantly reduce viral burden in people infected with HIV.
CytoDyn intends to continue to develop PRO 140 as a therapeutic
anti-viral agent in persons infected with HIV. For more information
on the Company please visit www.cytodyn.com.
About BIO CEO & Investor Conference
The 16th Annual BIO CEO & Investor Conference is the largest
independent investor conference focused on publicly-traded
biotechnology companies. The conference is designed to foster an
informative dialogue between institutional investors and senior
biotechnology executives about emerging and current investment
opportunities. The 2013 CEO & Investor Conference featured
1,380 partnering meetings, 148 company presentations, and 1,400
attendees, over half of which were investors.
Forward-Looking Statements
This press release includes forward-looking statements and
forward-looking information within the meaning of United States
securities laws. These statements and information represent
CytoDyn’s intentions, plans, expectations, and beliefs and are
subject to risks, uncertainties and other factors, many beyond
CytoDyn’s control. These factors could cause actual results to
differ materially from such forward-looking statements or
information. The words “believe,” “estimate,” “expect,” “intend,”
“attempt,” “anticipate,” “foresee,” “plan,” and similar expressions
and variations thereof identify certain of such forward-looking
statements or forward-looking information, which speak only as of
the date on which they are made.
CytoDyn disclaims any intention or obligation to publicly update
or revise any forward-looking statements or forward-looking
information, whether as a result of new information, future events
or otherwise, except as required by applicable law. Readers are
cautioned not to place undue reliance on these forward-looking
statements or forward-looking information. While it is impossible
to identify or predict all such matters, these differences may
result from, among other things, the inherent uncertainty of the
timing and success of and expense associated with research,
development, regulatory approval, and commercialization of
CytoDyn’s products and product candidates, including the risks that
clinical trials will not commence or proceed as planned; products
appearing promising in early trials will not demonstrate efficacy
or safety in larger-scale trials; future clinical trial data on
CytoDyn’s products and product candidates will be unfavorable;
funding for additional clinical trials may not be available;
CytoDyn’s products may not receive marketing approval from
regulators or, if approved, may fail to gain sufficient market
acceptance to justify development and commercialization costs;
competing products currently on the market or in development may
reduce the commercial potential of CytoDyn’s products; CytoDyn, its
collaborators or others may identify side effects after the product
is on the market; or efficacy or safety concerns regarding marketed
products, whether or not scientifically justified, may lead to
product recalls, withdrawals of marketing approval, reformulation
of the product, additional pre-clinical testing or clinical trials,
changes in labeling of the product, the need for additional
marketing applications, or other adverse events.
CytoDyn is also subject to additional risks and uncertainties,
including risks associated with the actions of its corporate,
academic, and other collaborators and government regulatory
agencies; risks from market forces and trends; potential product
liability; intellectual property litigation; environmental and
other risks; and risks that current and pending patent protection
for its products may be invalid, unenforceable, or challenged or
fail to provide adequate market exclusivity. There are also
substantial risks arising out of CytoDyn’s need to raise additional
capital to develop its products and satisfy its financial
obligations; the highly regulated nature of its business, including
government cost-containment initiatives and restrictions on
third-party payments for its products; the highly competitive
nature of its industry; and other factors set forth in CytoDyn’s
Quarterly Report on Form 10-Q for the quarter ended November 30,
2013 and other reports filed with the U.S. Securities and Exchange
Commission.
Investors and Media:Jenene Thomas Communications, LLCJenene
Thomas, 908-938-1475Investor Relations and Corporate Communications
Advisorjthomas@cytodyn.com
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Apr 2023 to Apr 2024